Shenzhen Pharmaceutical

Shenzhen Salubris Pharmaceuticals is a leading Chinese pharmaceutical company focused on the research, development, and commercialization of innovative drugs, primarily in the cardiovascular, metabolic, and orthopedic therapeutic areas. The company is well-known for its flagship product, Allisartan isoproxil (Xinlitai), a self-developed Class 1.1 innovative antihypertensive drug. Salubris has successfully transitioned from a generic-focused manufacturer to an innovation-driven enterprise with a robust pipeline of small molecules and biologics, including monoclonal antibodies targeting PCSK9 and IL-17A. Headquartered in Shenzhen, the company operates multiple R&D centers and manufacturing bases, maintaining a strong market presence in China while expanding its global footprint through strategic partnerships and clinical trials.